Brokerages Set OptimizeRx Corp. (NASDAQ:OPRX) PT at $17.57

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $17.5714.

OPRX has been the subject of several research analyst reports. Stifel Nicolaus lowered their price objective on OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a report on Friday, March 6th. Stephens lowered their target price on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. B. Riley Financial reaffirmed a “buy” rating and set a $11.00 target price (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Lake Street Capital lowered their target price on OptimizeRx from $24.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 6th. Finally, Roth Mkm lowered their target price on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 6th.

OptimizeRx Stock Up 0.3%

Shares of OptimizeRx stock opened at $6.43 on Thursday. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. The firm has a market cap of $120.63 million, a P/E ratio of 24.73 and a beta of 1.28. OptimizeRx has a fifty-two week low of $5.54 and a fifty-two week high of $22.25. The business has a 50-day moving average price of $6.92 and a 200 day moving average price of $11.89.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. On average, sell-side analysts forecast that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx declared that its board has approved a stock buyback plan on Thursday, March 5th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the company to purchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Hedge Funds Weigh In On OptimizeRx

Institutional investors have recently made changes to their positions in the stock. CenterBook Partners LP bought a new position in shares of OptimizeRx during the third quarter valued at approximately $6,331,000. Royce & Associates LP boosted its position in shares of OptimizeRx by 0.7% during the fourth quarter. Royce & Associates LP now owns 682,030 shares of the company’s stock worth $8,362,000 after buying an additional 4,700 shares during the period. Calamos Advisors LLC boosted its position in shares of OptimizeRx by 26.1% during the fourth quarter. Calamos Advisors LLC now owns 97,118 shares of the company’s stock worth $1,191,000 after buying an additional 20,116 shares during the period. State of Alaska Department of Revenue acquired a new position in shares of OptimizeRx during the fourth quarter worth approximately $62,000. Finally, Harbor Capital Advisors Inc. boosted its position in shares of OptimizeRx by 12.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock worth $305,000 after buying an additional 2,708 shares during the period. 76.47% of the stock is owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.